Lentinan inhibits colorectal cancer stemness by binding CD133 and suppressing the CD133/p85/p-AKT signaling axis
Our findings not only shed new light on the anti-tumor mechanism of lentinan, highlighting the scientific potential of natural polysaccharides in cancer treatment, but also offers new options for the clinical drug therapy of CRC.
Authors
- Jingyi Wang (ORCID: https://orcid.org/0000-0002-0860-8382)
- Junxi Liu (ORCID: https://orcid.org/0000-0001-6490-5704)
- Zihao He (ORCID: https://orcid.org/0000-0001-6588-1169)
- Yu Zhang (ORCID: https://orcid.org/0000-0003-0978-2363)
- Yan Liu (ORCID: https://orcid.org/0009-0003-5279-8376)
- Jinglin Wang (ORCID: https://orcid.org/0000-0002-3625-2993)
- Kaiping Wang (ORCID: https://orcid.org/0000-0002-7505-456X)
- Yang Luo (ORCID: https://orcid.org/0000-0002-4828-7130)
Institutions
- Union Hospital (HK)
- Wuhan Union Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-12-10
- DOI
- https://doi.org/10.3389/fphar.2025.1725716
- Citations
- 2
- Primary Topic
- Polysaccharides and Plant Cell Walls
- Type
- article
- Field-Weighted Citation Impact
- 3.50
Funders
- National Natural Science Foundation of China
- Huazhong University of Science and Technology
- Chinese Pharmaceutical Association